Genmab Holding B.v.

Genmab A+s

Genmab B.v.

Simone Oostindie

Frank Beurskens

Paul Parren

Esther Breij

Tuna Mutis

Martine E D Chamuleau

Hilma Van Der Horst

Ronald P Taylor

Margaret A Lindorfer

Marije Overdijk

Andreas Hollenstein

Edward Norbert Van Den Brink

Janine Schuurman

David Satijn

Aran Frank Labrijn

Rob N De Jong

Esther C W Breij

Patrick Engelberts

Kristel Kemper

Kristin Strumane

Bart-Jan De Kreuk

Farshid Alemdehy

Ronald Taylor

CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.

Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereof

Provided herein are combinations of first and second antibodies having modified Fc effector functions resulting from amino acid substitutions in the Fc region, the amino acid substitutions allow for co-dependent activation of effector functions such as CDC and/or ADCC. Also provided are combinations of first and second antibodies having agonistic activity or enhanced agonistic activity resulting from amino acid substitutions in the Fc region where the agonistic activity is co-dependent of both a first and second antibodies.

Antibody variant combinations and uses thereof

The present invention relates to anti-CD37antibodies having an Fc-Fc interaction enhancing substitution in the Fc-region of a human IgG, for use as a medicament in combination with anti-CD20 antibodies having an Fc-Fc interaction enhancing substitution in the Fc-region of a human IgG. The invention also relates to a novel composition of anti-CD37 antibodies having an Fc-Fc 5 interaction enhancing substitution and anti-CD20 antibodies having an Fc-Fc interaction enhancing substitution. In particular, the invention relates to compositions wherein the anti-CD37 antibody binds human CD37 and the anti-CD20 antibody binds human CD20. The invention also relates to compositions where the composition is a pharmaceutical composition and the use of such compositions in treatment of cancer and other diseases.

Anti-CD37 antibodies and anti-CD20 antibodies, compositions and methods of use thereof

The invention relates to multispecific antibodies binding to CD3 and CD30. The invention further provides pharmaceutical compositions comprising antibodies of the invention, nucleic acids encoding the antibodies, host cells that produce the antibodies, methods of producing the antibodies and uses of the antibodies, in particular for cancer therapy.

Antibodies binding to CD30 and CD3

Growing community of inventors

Utrecht, Netherlands

Simone Oostindie